Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nelson

Showing results (171-180 of 442) with videos related to

Pageof 45
Sort By:
AIDS (London, England)|July 27, 2006
No change to HIV-1 latency with valproate therapyAlan Steel, Sally Clark, Ian Teo, et al.
AIDS (London, England)|July 12, 2013
Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?Pierre-Marie Girard, Mark Nelson, Perry Mohammed, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 9, 2009
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individualsNaa Torshie Annan, Mark Nelson, Sundhiya Mandalia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control studyRachael Jones, Justin Stebbing, Mark Nelson, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2004
A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART)Justin Stebbing, Mark Nelson, Chloe Orkin, et al.
AIDS (London, England)|March 22, 2006
Do the mutations M046I and I047A confer resistance to kaletra?Huw Price, Rachael Jones, Milena Stevanovic, et al.
AIDS (London, England)|March 24, 2012
Discontinuation of Atripla as first-line therapy in HIV-1 infected individualsAndrew Scourfield, Jiexin Zheng, Suchitra Chinthapalli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective studyJustin Stebbing, Laura Waters, Liz Davies, et al.
Archives of Internal Medicine|September 24, 2008
Triple-class antiretroviral agent resistance in a large cohort: prevalence and clinical outcomesRachael Jones, Mark Nelson, Mark Bower, et al.
Frontiers in Neurology|March 26, 2015
Modulating central gain in tinnitus: changes in nitric oxide synthase in the ventral cochlear nucleusBen Coomber, Victoria L Kowalkowski, Joel I Berger, et al.
Pageof 45

Showing results (171-180 of 442) with videos related to

Sort By:
Pageof 45
AIDS (London, England)|July 27, 2006
No change to HIV-1 latency with valproate therapyAlan Steel, Sally Clark, Ian Teo, et al.
AIDS (London, England)|July 12, 2013
Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?Pierre-Marie Girard, Mark Nelson, Perry Mohammed, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 9, 2009
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individualsNaa Torshie Annan, Mark Nelson, Sundhiya Mandalia, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control studyRachael Jones, Justin Stebbing, Mark Nelson, et al.
The Journal of Antimicrobial Chemotherapy|February 6, 2004
A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART)Justin Stebbing, Mark Nelson, Chloe Orkin, et al.
AIDS (London, England)|March 22, 2006
Do the mutations M046I and I047A confer resistance to kaletra?Huw Price, Rachael Jones, Milena Stevanovic, et al.
AIDS (London, England)|March 24, 2012
Discontinuation of Atripla as first-line therapy in HIV-1 infected individualsAndrew Scourfield, Jiexin Zheng, Suchitra Chinthapalli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective studyJustin Stebbing, Laura Waters, Liz Davies, et al.
Archives of Internal Medicine|September 24, 2008
Triple-class antiretroviral agent resistance in a large cohort: prevalence and clinical outcomesRachael Jones, Mark Nelson, Mark Bower, et al.
Frontiers in Neurology|March 26, 2015
Modulating central gain in tinnitus: changes in nitric oxide synthase in the ventral cochlear nucleusBen Coomber, Victoria L Kowalkowski, Joel I Berger, et al.
Pageof 45